<DOC>
	<DOCNO>NCT02719158</DOCNO>
	<brief_summary>This 1-month , prospective , multicenter , randomize , dose-ranging , sham-controlled , blind study eligible subject either unilateral bilateral acute otitis medium tympanostomy tube ( AOMT ) receive single administration 6 mg OTO-201 , 12 mg OTO-201 , sham affect ear ( ) .</brief_summary>
	<brief_title>Dose Ranging Study OTO-201 AOMT</brief_title>
	<detailed_description />
	<mesh_term>Otitis</mesh_term>
	<mesh_term>Otitis Media</mesh_term>
	<mesh_term>Ciprofloxacin</mesh_term>
	<criteria>Inclusion Criteria include , limited : Subject male female age 6 month 17 year , inclusive Subject clinical diagnosis acute otitis medium tympanostomy tube ( AOMT ) Subject 's caregiver willing comply protocol attend study visit Exclusion Criteria include , limited : Subject history sensorineural hearing loss Subject tympanic membrane perforation surgical tympanostomy tube perforation Subject history know immunodeficiency disease</criteria>
	<gender>All</gender>
	<minimum_age>6 Months</minimum_age>
	<maximum_age>17 Years</maximum_age>
	<verification_date>August 2016</verification_date>
	<keyword>Acute otitis medium tympanostomy tube</keyword>
	<keyword>OTIPRIO</keyword>
</DOC>